Abstract: Disclosed is a debt repayment lottery/game system and method that allows a pool of players with existing loan debt such as student loans, mortgages, personal loans, credit card debt, automobile loans, boat loans, plane loans, investment loans, and other such debt. The winning payout is made to a third party versus the actual winner. Winner selection is based on various random and non-random factors. Each player is required to pay a fee that may be monetary or non-monetary to play in the lottery or other game. Such fees, or otherwise raised funds, are aggregated and pooled and are used, in part, to directly pay down the outstanding debt. There may be multiple winners depending on the amount of debt owed not necessarily the pool size. A safeguard or fail-safe mechanism prevents the player from purchasing more entries than debt owed.

Abstract: Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to obtain a comparable target hematocrit and treat anemia. Alternatively, a lower molar amount of a hyperglycosylated analog may be administered to obtain a comparable target hematocrit and treat anemia. Also disclosed are new hyperglycosylated erythopoietin analogs, methods of production of the analogs, and compositions comprising the analogs.

Abstract: Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to obtain a comparable target hematocrit and treat anemia. Alternatively, a lower molar amount of a hyperglycosylated analog may be administered to obtain a comparable target hematocrit and treat anemia. Also disclosed are new hyperglycosylated erythopoietin analogs, methods of production of the analogs, and compositions comprising the analogs.

Abstract: Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to obtain a comparable target hematocrit and treat anemia. Alternatively, a lower molar amount of a hyperglycosylated analog may be administered to obtain a comparable target hematocrit and treat anemia. Also disclosed are new hyperglycosylated erythopoietin analogs, methods of production of the analogs, and compositions comprising the analogs.

Abstract: Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to obtain a comparable target hematocrit and treat anemia. Alternatively, a lower molar amount of a hyperglycosylated analog may be administered to obtain a comparable target hematocrit and treat anemia. Also disclosed are new hyperglycosylated erythopoietin analogs, methods of production of the analogs, and compositions comprising the analogs.

Abstract: Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to obtain a comparable target hematocrit and treat anemia. Alternatively, a lower molar amount of a hyperglycosylated analog may be administered to obtain a comparable target hematocrit and treat anemia. Also disclosed are new hyperglycosylated erythropoietin analogs, methods of production of the analogs, and compositions comprising the analogs.

Abstract: Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to obtain a comparable target hematocrit and treat anemia. Alternatively, a lower molar amount of a hyperglycosylated analog may be administered to obtain a comparable target hematocrit and treat anemia. Also disclosed are new hyperglycosylated erythopoietin analogs, methods of production of the analogs, and compositions comprising the analogs.

Abstract: Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to obtain a comparable target hematocrit and treat anemia. Alternatively, a lower molar amount of a hyperglycosylated analog may be administered to obtain a comparable target hematocrit and treat anemia. Also disclosed are new hyperglycosylated erythropoietin analogs, methods of production of the analogs, and compositions comprising the analogs.

Abstract: Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to obtain a comparable target hematocrit and treat anemia. Alternatively, a lower molar amount of a hyperglycosylated analog may be administered to obtain a comparable target hematocrit and treat anemia. Also disclosed are new hyperglycosylated erythopoietin analogs, methods of production of the analogs, and compositions comprising the analogs.

Abstract: An electronic fly trap apparatus having a housing with an upper housing aperture. A removable front panel is placed over the upper housing aperture, and at least one fly access aperture extends through the removable front panel. At least one light is positioned in the lower portion of the housing. Flies are drawn into the housing by the light, and the warmth and sound generated by the light. A disposable sheet having a plurality of apertures therethrough is positioned above the source of light. A sticky adhesive is disposed upon the upper surface of the disposable sheet. A curved, light reflective panel extends behind and above the disposable sheet. Reflected light passing through the plurality of apertures in the disposable sheet, are redirected by the light reflective surface to pass through the access aperture(s) in the front panel, to attract flying insects within the housing.

Abstract: An electronic fly trap apparatus having a housing with a cover placed over the top portion of the housing, and at least one flying insect access aperture extends through a portion of the cover. A light is positioned in the lower portion of the housing. A disposable sheet having a plurality of apertures therethrough is positioned on the housing above the source of light. A sticky adhesive is disposed upon the upper surface of the disposable sheet. Light and heat pass through the apertures in the disposable sheet into a space provided beneath the cover. A reflective panel is placed beneath the light to redirect primary light through the plurality of apertures. Flying insects pass into the apparatus through at least one access aperture, and are entrapped upon the sticky adhesive on the disposable sheet when they seek the source of the light.

Abstract: A method for genetically engineering cells to produce soluble and secretable Golgi processing enzymes instead of naturally occurring membrane-bound enzymes. Cells are genetically engineered to express glycosyltransferases which lack both a membrane anchor and a retention signal. The resulting altered enzyme becomes soluble and secretable by the cell without losing its catalytic activity. Secretion of the soluble glycosyltransferase by the cell provides for increased production and simplified recovery of glycosyltransferase.

Abstract: A method for genetically engineering cells to produce soluble and secretable Golgi processing enzymes instead of naturally occurring membrane-bound enzymes. Cells are genetically engineered to express glycosyltransferases which lack both a membrane anchor and a retention signal. The resulting altered enzyme becomes soluble and secretable by the cell without losing its catalytic activity. Secretion of the soluble glycosyltransferase by the cell provides for increased production and simplified recovery of glycosyltransferase.

Abstract: A microbial shuttle vector is disclosed which is independently replicative in bacterial cells and mammalian cells and includes in its DNA sequence bacterial plasmid sequences allowing selection and replication in bacterial cells, an SV40 viral origin of replication, and either an SV40 functional "early gene" promoter and functional "early gene" terminator or an SV40 functional "late gene" promoter and functional "late gene" terminator, the vector having a unique restriction endonuclease enzyme recognition site between the promoter and terminator for insertion of an exogenous gene. The presence of restriction endonuclease enzyme recognition sites facilitative of insertion of a viral functional "late gene" into the "early gene" promoter/terminator vector in a single step allows for conversion of the shuttle vector into a lytic vector of an exogenous gene.

Abstract: A device which can dispense at least one pesticide which comprises a base unit (10) containing tanks (40, 42) for the pesticides and a wand (100) including valves (212, 134) to control dispensing of the pesticides, an electrode (280) to place an electrostatic charge on one pesticide, and a pulsing unit (128) to pulse the flow of one pesticide.

Abstract: A method for genetically engineering cells to produce soluble and secretable Golgi processing enzymes instead of naturally occurring membrane-bound enzymes. Cells are genetically engineered to express glycosyltransferases which lack both a membrane anchor and a rThis invention was made with government support under Grant Contract Nos. GM-27904 and GM-11557 awarded by the National Institute of Health. The government has certain rights in this invention. The publications and other reference materials referred to herein to describe the background of the invention and to provide additional detail regarding its practice are hereby incorporated by reference. For convenience, the reference materials are numerically referenced and grouped in the appended bibliography.

Abstract: An electronic trap for flying insects. Insects such as flies are attracted to the trap by a UV light source and then alight on a conductive grid with carefully spaced alternative areas of opposite potential. A pulsed cycle of electricity stuns the insects, which then dive down to a trap at the bottom of the device and, being entrapped, die.

Abstract: A spring collar coupling (10) is provided for joining opposing fluid conduits. Basically, the spring collar coupling comprises a spring collar (20) in cooperative engagement with a first and second flange member (40, 60) functionally joined by the application of a coaxial force, the insertion of a bayonet locking ring (70) and release of the pressure force to effect a coupling of the aforesaid components.